At the end of the latest market close, CRISPR Therapeutics AG (CRSP) was valued at $110.56. In that particular session, Stock kicked-off at the price of $112.47 while reaching the peak value of $119.54 and lowest value recorded on the day was $112.04. The stock current value is $117.65.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Recently in News on May 12, 2021, Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for presentation during the European Hematology Association (EHA) 2021 Virtual Congress. You can read further details here

CRISPR Therapeutics AG had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $220.20 on 01/15/21, with the lowest value was $95.11 for the same time period, recorded on 05/11/21.

CRISPR Therapeutics AG (CRSP) full year performance was 76.15%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CRISPR Therapeutics AG shares are logging -46.57% during the 52-week period from high price, and 102.77% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $58.02 and $220.20.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1345025 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CRISPR Therapeutics AG (CRSP) recorded performance in the market was -23.16%, having the revenues showcasing -21.03% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.44B, as it employees total of 410 workers.

The Analysts eye on CRISPR Therapeutics AG (CRSP)

During the last month, 13 analysts gave the CRISPR Therapeutics AG a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 2 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 139.84, with a change in the price was noted -50.85. In a similar fashion, CRISPR Therapeutics AG posted a movement of -30.18% for the period of last 100 days, recording 2,067,760 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CRSP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Technical rundown of CRISPR Therapeutics AG (CRSP)

Raw Stochastic average of CRISPR Therapeutics AG in the period of last 50 days is set at 53.06%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 53.06%. In the last 20 days, the company’s Stochastic %K was 43.58% and its Stochastic %D was recorded 38.15%.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Considering, the past performance of CRISPR Therapeutics AG, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -23.16%. Additionally, trading for the stock in the period of the last six months notably improved by 8.36%, alongside a boost of 76.15% for the period of the last 12 months. The shares increased approximately by 16.49% in the 7-day charts and went up by -5.83% in the period of the last 30 days. Common stock shares were lifted by -21.03% during last recorded quarter.

Source link